C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel

Kite Pharma, Gilead Sciences, Inc. Yescarta (Axicabtagene ciloleucel) [package insert], https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/Package-Insert---YESCARTA.pdf [accessed 27 May 2019]. Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N Engl J Med, 377, 2531, 10.1056/NEJMoa1707447 Brudno, 2016, Toxicities of chimeric antigen receptor T cells: recognition and management, Blood, 127, 3321, 10.1182/blood-2016-04-703751 Garcia Borrega, 2019, In the eye of the storm: immune-mediated toxicities associated with CAR-T cell therapy, Hemasphere, 3, 10.1097/HS9.0000000000000191 Lee, 2019, ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells, Biol Blood Marrow Transplant, 25, 625, 10.1016/j.bbmt.2018.12.758 Neelapu, 2018, Chimeric antigen receptor T-cell therapy – assessment and management of toxicities, Nat Rev Clin Oncol, 15, 47, 10.1038/nrclinonc.2017.148 Pennisi, 2020, Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management, Blood Adv, 4, 676, 10.1182/bloodadvances.2019000952 Rivera, 2020, CAR T-cell-associated neurotoxicity: current management and emerging treatment strategies, Crit Care Nurs Q, 43, 191, 10.1097/CNQ.0000000000000302 Lin RJ, Lobaugh SM, Pennisi M, Chan HT, Batlevi Y, Ruiz JD, et al. Haematologica. 2020 Feb 20; haematol. 2019; 243246. https://doi.org/10.3324/haematol.2019.243246. Online ahead of print. Qin, 2019, Prognostic value of pre-therapy C-reactive protein level in diffuse large B-cell lymphoma: a meta-analysis, Leuk Lymphoma, 60, 358, 10.1080/10428194.2018.1482540 Sun, 2018, An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era, BMC Cancer, 18, 5, 10.1186/s12885-017-3931-z Troppan, 2014, C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients, Br J Cancer, 111, 55, 10.1038/bjc.2014.277 Wang, 2016, Pretreatment C-reactive protein was an independent prognostic factor for patients with diffuse large B-cell lymphoma treated with RCHOP, Clin Chim Acta, 459, 150, 10.1016/j.cca.2016.05.033 Gulcher, 2016, Elevated C-reactive protein levels at ICU discharge as a predictor of ICU outcome: a retrospective cohort study, Ann Intensive Care, 6, 5, 10.1186/s13613-016-0105-0 Ranzani OT, Prada LF, Zampieri FG, et al. Failure to reduce C-reactive protein levels more than 25% in the last 24 hours before intensive care unit discharge predicts higher in-hospital mortality: a cohort study. J Crit Care 2012; 27: 525.e9–e15. Lee, 2014, Current concepts in the diagnosis and management of cytokine release syndrome, Blood, 124, 188, 10.1182/blood-2014-05-552729 Allen, 2008, Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis, Pediatr Blood Cancer, 50, 1227, 10.1002/pbc.21423 Al-Samkari, 2018, Hemophagocytic lymphohistiocytosis, Annu Rev Pathol, 13, 27, 10.1146/annurev-pathol-020117-043625 Kell, 2014, Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells, Metallomics, 6, 748, 10.1039/C3MT00347G Teachey, 2016, Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia, Cancer Discov, 6, 664, 10.1158/2159-8290.CD-16-0040 Varadarajan, 2019, Management of T-cell engaging immunotherapy complications, Cancer J, 25, 223, 10.1097/PPO.0000000000000377 Alkhateeb, 2013, The significance of ferritin in cancer: anti-oxidation, inflammation and tumorigenesis, Biochim Biophys Acta, 1836, 245